The field of clinical trials has evolved rapidly in the past decade, specifically in the development of novel methods to design and analyse trials. This presentation will highlight a few specific examples across phase 1 to phase 3 trials. Phase 1 trials are usually designed to find the Maximum Tolerated Dose (MTD) with some target toxicity rate. Current methods to determine MTD have limitations. This talk will highlight the application of a new Bayesian optimal interval (BOIN) design that aims to overcome some of these challenges. Missing data is a perennial problem for researchers, both within observational studies and in RCTs. The amount of missing data as well as the nature of missingness can pose a challenge in the analysis of such data. The multiple imputation approach will be highlighted in this talk.